Alx Oncology Holdings Inc
ALXO
Get informed when a big investor buys or sells
+ FollowMarket Cap$228.76M
Close$
$0.21
85.9% downside
Current Fair Value
85.9% downsideOvervalued by 85.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $228.76 Million |
|---|---|
| Enterprise Value | $215.77 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.9 |
| Beta | 0.4 |
| Outstanding Shares | 135,639,684 |
Return
| Return on Equity | -59.40% |
|---|---|
| Return on Assets | -50.30% |
| Return on Invested Capital | -56.53% |
Valuation & Multiples
| P/E Ratio | -1.5 |
|---|---|
| PEG | 4.89 |
| Price to Sales | - |
| Price to Book Ratio | 1.47 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.61 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.55% |
|---|---|
| Total Calls | 61,000▲ 19.37% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.73%▼ 12.41% |
|---|---|
| Total Invested | $218.39M▲ 15.54% |
| Investors Holding | 98▲ 26.00% |
ESG Score
No data
About Alx Oncology Holdings Inc
23 employeesALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system. ALX Oncology Holdings serves patients in the State of California.